

## Rianna Modi

Associate

Washington, D.C.

### Biography

Rianna enjoys assisting clients in navigating the complex regulatory requirements of the rapidly evolving healthcare industry.

She advises a variety of health and life sciences clients on federal and state legal questions, including in relation to Medicare coverage and reimbursement, fraud and abuse, and drug pricing and access. She appreciates opportunities to advocate for clients interfacing with government entities and using her understanding of the intersection between law and policy to do so. Rianna also maintains an active pro bono practice, in which she assists non-profit organizations on abortion and reproductive justice issues and represents individuals in immigration proceedings.

Before joining the firm, Rianna received her J.D. from the University of California, Berkeley, School of Law where she was a member of the California Law Review, the programs director for the Ecology Law Quarterly journal, and a student leader of the South Asian Law Students Association and Disability Rights Project.

### Latest thinking and events

- News
  - CMS Issues Final Guidance on IRA 2027 Drug Price Negotiation Program, 2026-27 MFP Effectuation
- News



### Phone

+1 202 637 5600

### Fax

+1 202 637 5910

### Email

[rianna.modi@hoganlovells.com](mailto:rianna.modi@hoganlovells.com)

---

### Education and admissions

#### Education

J.D., University of California, Berkeley School of Law, 2022

B.S., Rutgers, The State University of New Jersey, summa cum laude, 2019

---

### Bar admissions and qualifications

District of Columbia

Pennsylvania

---

- CMS issues Final Rule adopting some but not all proposed changes to the Medicaid Drug Rebate Program
- News
  - Breaking News for Breakthrough Devices: CMS Finalizes Transitional Coverage for Emerging Technologies Pathway
- News
  - Tortoise and Hare: Congress may overtake CMS in years-long race to set Medicare breakthrough device coverage
- News
  - CMS Issues Draft Guidance on Inflation Reduction Act (IRA) Drug Price Negotiation Program for 2027
- News
  - HRSA issues 340B Program final rule modifying administrative dispute resolution process